REMEGEN (09995) saw its stock price climb 7.29% in early trading, reaching HK$110.40 with trading volume of HK$359 million.

According to REMEGEN's official announcement, the 2025 European Society for Medical Oncology (ESMO) annual meeting will be held in Berlin, Germany from October 17-21 local time. REMEGEN has successfully secured inclusion of 11 original research results, with multiple clinical research data being disclosed internationally for the first time.

The company will showcase several significant research achievements at the conference. Notably, the RC48-C016 Phase III clinical study of disitamab vedotin combination therapy for first-line urothelial carcinoma has been selected for "Late-Breaking Abstracts (LBA)," demonstrating the important academic value of this research. Additionally, the company will present 10 additional studies covering multiple tumor types and related treatment strategies, including 2 short oral presentations and 8 poster presentations. These cover areas such as urothelial carcinoma, gastric cancer, and gynecological tumors, comprehensively demonstrating REMEGEN's leading capabilities in ADC drug combination therapies.